Overview
Plain-language guide to the difference between 503A patient-specific compounding pharmacies and 503B FDA-registered outsourcing facilities.
Related guides
- Semaglutide Cost Guide — Brand vs Compounded Pricing
- Semaglutide Side Effects — What Patients Report
- Semaglutide Dosing Schedule
- BMI Eligibility for Semaglutide Weight Management
- Compounded vs Brand-Name Semaglutide
- Semaglutide Insurance Coverage
- How Semaglutide Works — Mechanism Explained
- Semaglutide and Cardiovascular Health
Key facts, checked November 20, 2026
A 503A pharmacy is licensed by its state and compounds for an individual patient’s prescription. A 503B outsourcing facility registers with FDA, follows current good manufacturing practice and may compound in bulk. For GLP-1s, FDA’s 503B proposal (91 FR 23431) would keep tirzepatide, semaglutide and liraglutide off the 503B bulks list; comments closed July 30, 2026 and no final notice had appeared by November 20, 2026. Neither type of facility makes a compounded drug FDA-approved, and FDA’s 2026 warning letters objected to calling pharmacies “FDA-licensed.” See FDA’s page on unapproved GLP-1 drugs.